News
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback